

# Michael D Rawlins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4444373/publications.pdf>

Version: 2024-02-01

47  
papers

3,515  
citations

393982

19  
h-index

243296

44  
g-index

50  
all docs

50  
docs citations

50  
times ranked

3893  
citing authors

#	ARTICLE	IF	CITATIONS
1	NICE comes of age. <i>Significance</i> , 2020, 17, 38-41.	0.3	1
2	The UK's Life Sciences Strategy: opportunities for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2175-2177.	1.1	41
3	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.	1.0	19
4	Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review. <i>BMJ Open</i> , 2016, 6, e009070.	0.8	49
5	Cost, Effectiveness, and Value. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1447.	3.8	8
6	The Prevalence of Huntington's Disease. <i>Neuroepidemiology</i> , 2016, 46, 144-153.	1.1	244
7	A simple tragedy with a special resonance. <i>Journal of Health Services Research and Policy</i> , 2015, 20, 124-125.	0.8	0
8	National Institute for Clinical Excellence: NICE works. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 211-219.	1.1	19
9	The "Saatchi bill" will allow responsible innovation in treatment. <i>BMJ, The</i> , 2014, 348, g2771-g2771.	3.0	14
10	Clinical pharmacologists in pharmacoeconomics: what is their role?. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 105-107.	1.3	0
11	EVIDENCE, VALUES, AND DECISION MAKING. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 233-238.	0.2	15
12	Engaging with health-care policy. <i>Lancet, The</i> , 2014, 383, S7-S8.	6.3	3
13	Author's reply to Poole, Conway, Bewley, Sundar, and Chalmers and Firkins. <i>BMJ, The</i> , 2014, 348, g3152-g3152.	3.0	0
14	Pharmacopolitics: reflections on a subspecialty of clinical pharmacology?. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 11-15.	0.8	12
15	NICE times: a valedictory dispatch. <i>Lancet, The</i> , 2013, 381, 2225-2227.	6.3	3
16	Clinical pharmacology in health care, teaching and research. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1219-1220.	1.1	6
17	A Population Approach to the Rational Use of Therapeutic Interventions. <i>Clinical Therapeutics</i> , 2013, 35, 1634-1638.	1.1	7
18	What's happening at NICE?. <i>Clinical Medicine</i> , 2013, 13, 13-18.	0.8	11

#	ARTICLE	IF	CITATIONS
19	NICE: Moving Onward. <i>New England Journal of Medicine</i> , 2013, 369, 3-5.	13.9	24
20	Michael Rawlins: Pet hate is the Daily Mail. <i>BMJ, The</i> , 2013, 347, f6321-f6321.	3.0	1
21	Article Commentary: Of snarks, boojums and national drug charts. <i>Journal of the Royal Society of Medicine</i> , 2013, 106, 9-9.	1.1	1
22	Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1156-1160.	0.9	167
23	HTA AND VALUE - A COMMENTARY. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 374-375.	0.2	0
24	Comparative effectiveness research: a view from the other side of the pond. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 293-295.	0.6	2
25	Evidence and Quality, Practicalities and Judgments: Some Experience from NICE. <i>Healthcare Quarterly</i> , 2012, 15, 66-69.	0.7	4
26	Reflections: NICE, Health Economics, and Outcomes Research. <i>Value in Health</i> , 2012, 15, 568-569.	0.1	3
27	Crossing the fourth hurdle. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 855-860.	1.1	15
28	The opportunity cost of cancer care: a statement from NICE. <i>Lancet Oncology, The</i> , 2011, 12, 931-932.	5.1	13
29	Pharmacogenetics and cost-effectiveness analysis: a two-way street. <i>Drug Discovery Today</i> , 2011, 16, 873-877.	3.2	9
30	Commentary: The death of clinical freedom. <i>International Journal of Epidemiology</i> , 2011, 40, 859-861.	0.9	3
31	Pharmacoeconomics: NICE's approach to decision-making. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 346-349.	1.1	126
32	Huntington's disease out of the closet?. <i>Lancet, The</i> , 2010, 376, 1372-1373.	6.3	63
33	The decade of NICE. <i>Lancet, The</i> , 2009, 374, 351-352.	6.3	22
34	Helping to provide high quality care in primary care. <i>Ulster Medical Journal</i> , 2009, 78, 82-3.	0.2	1
35	De testimonio: on the evidence for decisions about the use of therapeutic interventions. <i>Lancet, The</i> , 2008, 372, 2152-2161.	6.3	271
36	De Testimonio: on the evidence for decisions about the use of therapeutic interventions. <i>Clinical Medicine</i> , 2008, 8, 579-588.	0.8	121

#	ARTICLE	IF	CITATIONS
37	When are randomised trials unnecessary? Picking signal from noise. BMJ: British Medical Journal, 2007, 334, 349-351.	2.4	487
38	Paying for modern cancer care—a global perspective. Lancet Oncology, The, 2007, 8, 749-751.	5.1	18
39	Pharmacopolitics and deliberative democracy. Clinical Medicine, 2005, 5, 471-475.	0.8	48
40	National Institute for Clinical Excellence and its value judgments. BMJ: British Medical Journal, 2004, 329, 224-227.	2.4	651
41	Cutting the cost of drug development?. Nature Reviews Drug Discovery, 2004, 3, 360-364.	21.5	163
42	In pursuit of quality: the National Institute for Clinical Excellence. Lancet, The, 1999, 353, 1079-1082.	6.3	148
43	New active substances authorized in the United Kingdom between 1972 and 1994. British Journal of Clinical Pharmacology, 1998, 45, 151-156.	1.1	69
44	The efficacy of locally applied aspirin and acetaminophen in postoperative pain after third molar surgery. Clinical Pharmacology and Therapeutics, 1992, 52, 292-296.	2.3	28
45	The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 1989, 9, 297-301.	3.6	578
46	Tests of the times. Nature, 1986, 323, 366-366.	13.7	0
47	Therapeutics, Evidence and Decision-Making. , 0, , .		9